Chiari, Rita

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Soria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., et al. (2017) · The Lancet

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 1,151

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Solomon, B. J., Besse, B., Bauer, T. M., Felip, E., Soo, R. A., Camidge, D. R., Chiari, R., Bearz, A., Lin, C.-C., Gadgeel, S. M., et al. (2018) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 791

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Cortellini, A., Bersanelli, M., Buti, S., Cannita, K., Santini, D., Perrone, F., Giusti, R., Tiseo, M., Michiara, M., Di Marino, P., et al. (2019) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersCancer Risks and Factors

Cited by 413

Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis

Ricciuti, B., Genova, C., De Giglio, A., Bassanelli, M., Dal Bello, M. G., Metro, G., Brambilla, M., Baglivo, S., Grossi, F., & Chiari, R. (2019) · Journal of Cancer Research and Clinical Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 345

Impact of TP53 Mutations on Outcome in EGFR -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

Canale, M., Petracci, E., Delmonte, A., Chiadini, E., Dazzi, C., Papi, M., Capelli, L., Casanova, C., De Luigi, N., Mariotti, M., et al. (2017) · Clinical Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 288

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

Cortellini, A., Tucci, M., Adamo, V., Stucci, L. S., Russo, A., Tanda, E. T., Spagnolo, F., Rastelli, F., Bisonni, R., Santini, D., et al. (2020) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis

Cited by 275

Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients

Marchetti, A., Palma, J. F., Felicioni, L., De Pas, T. M., Chiari, R., Del Grammastro, M., Filice, G., Ludovini, V., Brandes, A., Chella, A., et al. (2015) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 182

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations

Passiglia, F., Cappuzzo, F., Alabiso, O., Bettini, A. C., Bidoli, P., Chiari, R., Defferrari, C., Delmonte, A., Finocchiaro, G., Francini, G., et al. (2019) · British Journal of Cancer

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 81

Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations

Passaro, A., Prelaj, A., Bonanno, L., Tiseo, M., Tuzi, A., Proto, C., Chiari, R., Rocco, D., Genova, C., Sini, C., et al. (2019) · Clinical Lung Cancer

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 54